View Document Preview and Link Document Date: 2015-01-16 01:00:00 Open Document File Size: 120,62 KB Share Result on Facebook
City Philadelphia / Basel / Marseille / / Company Sofipaca / Turenne Capital / Genentech / Vesale Partners / OTC Agregator / Roche Group / Chugai Pharmaceutical / Amundi Private Equity Funds / ACG Management / Trophos / / Country Switzerland / France / Japan / United States / / Currency CHF / EUR / / / Event M&A / / / IndustryTerm biotechnology / research-focused healthcare / pharmaceuticals / diabetes management / stage pharmaceutical company developing innovative therapeutics / / MedicalCondition tissue-based cancer / progressive muscle weakness / common rare diseases / muscle weakness / grievous disease / neuromuscular disease / severe scoliosis / autosomal recessive genetic disease / scoliosis / spinal muscular atrophy / genetic disease / disease / serious disease / profound muscle weakness / respiratory infections / diabetes / infectious diseases / genetic neuromuscular disease / severe respiratory infections / / MedicalTreatment antibiotics / chemotherapy / / Organization World Health Organization / French Ministry of Economy / American Academy of Neurology / French Muscular Dystrophy Association / European Medicines Agency / Society for Maternal-Fetal Medicine / US Food and Drug Administration / European Union / / Person Sandra Horning / Nicolas Dunant / Ulrike Engels-Lange / Nicole Rüppel / Nina Schwab-Hautzinger / Claudia Schmitt / F. Hoffmann-La / Christine Placet / / / Position Chief Executive Officer / Chief Medical Officer and Head of Global Product Development / leader / majority shareholder / Head / / PublishedMedium Science Daily / / Technology neuroscience / biotechnology / in vitro diagnostics / chemotherapy / / URL www.roche.com / / SocialTag 
Microsoft Word - 150116_Trophos_en